Literature DB >> 15056653

Solution structure and backbone dynamics of the non-receptor protein-tyrosine kinase-6 Src homology 2 domain.

Eunmi Hong1, Joon Shin, Han-Ie Kim, Seung-Taek Lee, Weontae Lee.   

Abstract

Human protein-tyrosine kinase-6 (PTK6, also known as breast tumor kinase (Brk)) is a member of the non-receptor protein-tyrosine kinase family and is expressed in two-thirds of all breast tumors. To understand the structural basis of PTK6 function, we have determined the solution structure and backbone dynamics of the PTK6-Src homology 2 (SH2) domain using multidimensional NMR spectroscopy. The solution structure clearly indicates that the SH2 domain of human PTK6 contains a consensus alpha/beta-fold and a Tyr(P) peptide binding surface, which are common to other SH2 domains. However, two of the alpha-helices (alphaA and alphaB) are located on opposite faces of the central beta-sheet. In addition, the topological arrangement of a central four-stranded antiparallel beta-sheet (strands betaA, betaB, betaC, and betaD) differs from that of other Src family members. Backbone dynamics and Tyr(P) peptide titration experiments revealed that the putative ligand binding sites of the PTK6-SH2 domain undergo distinctive internal motions when compared with other regions of the protein. Surface plasmon resonance analysis showed that the Tyr(P) peptide had a dissociation constant of about 60 microm, which is substantially weaker binding than previously reported for Src family members. The solution structure together with data from the ligand binding mode of PTK6-SH2 provides insight into the molecular basis of the autoinhibitory role of PTK6.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15056653     DOI: 10.1074/jbc.M313185200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Loops govern SH2 domain specificity by controlling access to binding pockets.

Authors:  Tomonori Kaneko; Haiming Huang; Bing Zhao; Lei Li; Huadong Liu; Courtney K Voss; Chenggang Wu; Martin R Schiller; Shawn Shun-Cheng Li
Journal:  Sci Signal       Date:  2010-05-04       Impact factor: 8.192

Review 2.  Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapy.

Authors:  Haroon A Hussain; Amanda J Harvey
Journal:  World J Clin Oncol       Date:  2014-08-10

Review 3.  Brk/PTK6 signaling in normal and cancer cell models.

Authors:  Julie H Ostrander; Andrea R Daniel; Carol A Lange
Journal:  Curr Opin Pharmacol       Date:  2010-09-09       Impact factor: 5.547

Review 4.  Building a better understanding of the intracellular tyrosine kinase PTK6 - BRK by BRK.

Authors:  Patrick M Brauer; Angela L Tyner
Journal:  Biochim Biophys Acta       Date:  2010-02-26

5.  Protein tyrosine kinase 6 directly phosphorylates AKT and promotes AKT activation in response to epidermal growth factor.

Authors:  Yu Zheng; Maoyu Peng; Zebin Wang; John M Asara; Angela L Tyner
Journal:  Mol Cell Biol       Date:  2010-07-06       Impact factor: 4.272

Review 6.  Targeting protein tyrosine kinase 6 in cancer.

Authors:  Milica B Gilic; Angela L Tyner
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-09-18       Impact factor: 10.680

Review 7.  Putting the BRK on breast cancer: From molecular target to therapeutics.

Authors:  Hui Li Ang; Yi Yuan; Xianning Lai; Tuan Zea Tan; Lingzhi Wang; Benjamin BoJun Huang; Vijay Pandey; Ruby Yun-Ju Huang; Peter E Lobie; Boon Cher Goh; Gautam Sethi; Celestial T Yap; Ching Wan Chan; Soo Chin Lee; Alan Prem Kumar
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

8.  Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6.

Authors:  Amanda M Weaver; Corinne M Silva
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.